| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 09/01/2009 | US7582440 Imaging, diagnosis and treatment of disease |
| 09/01/2009 | US7582313 Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| 09/01/2009 | CA2438799C Preventative of therapeutic agent for inflammatory respiratory tract disease |
| 09/01/2009 | CA2432428C Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 09/01/2009 | CA2367368C Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands |
| 09/01/2009 | CA2238360C Enzymatic method and compositions for treating intravitreal hemorrhagic blood |
| 08/27/2009 | WO2009105756A2 Protection of neural retina by reduction of rod metabolism |
| 08/27/2009 | WO2009105534A2 Ophthalmic nsaids as adjuvants |
| 08/27/2009 | WO2009105440A1 Beta-lactams for reducing intraocular pressure |
| 08/27/2009 | WO2009105438A1 Therapeutic substituted lactams |
| 08/27/2009 | WO2009104822A1 Medical preparation for retinal ischemia disorders, containing hydrogen molecules |
| 08/27/2009 | WO2009104045A1 Ophthalmic gemifloxacin compositions for the treatment of ocular infections |
| 08/27/2009 | WO2009103755A1 Novel use of 3,3'-diindolylmethane |
| 08/27/2009 | WO2009103160A1 Treatment and prevention of dry age-related macular degeneration by activating cd36 |
| 08/27/2009 | WO2009063215A3 Use of crth2 antagonist compounds |
| 08/27/2009 | WO2009063202A3 Use of crth2 antagonist compounds |
| 08/27/2009 | WO2009020894A3 RNAι-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA |
| 08/27/2009 | US20090215995 isolated nucleic acids encoding B7-related polypeptides, including BSL3, which modulate cells that are important for immune and inflammatory responses, such as T-cells |
| 08/27/2009 | US20090215851 Method of Preparing a Porphyrin Derivative, a Porphyrin Derivative, Use of Said Porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative |
| 08/27/2009 | US20090215740 Therapeutic substituted beta-lactams |
| 08/27/2009 | US20090215736 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid |
| 08/27/2009 | US20090215703 PAR-2 Agonist |
| 08/27/2009 | US20090215679 Disease-associated proteins |
| 08/27/2009 | US20090215671 Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists |
| 08/27/2009 | US20090215151 Two-Step Immunization Procedure Against Chlamydia Infection |
| 08/27/2009 | US20090214681 Use of black soybean for treating ophthalmic diseases |
| 08/27/2009 | US20090214676 Method for treating ocular demodex |
| 08/27/2009 | US20090214505 For treating an excess of a substrate for a hyaluronidase, such as reducing scar tissue |
| 08/27/2009 | US20090214485 Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy |
| 08/27/2009 | US20090214478 Method of treating ocular diseases by gene therapy |
| 08/27/2009 | US20090214470 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 08/27/2009 | CA2752851A1 Treatment and prevention of dry age-related macular degeneration by activating cd36 |
| 08/27/2009 | CA2716185A1 Compositions and methods for treating ophthalmic diseases |
| 08/27/2009 | CA2716110A1 Ophthalmic nsaids as adjuvants |
| 08/26/2009 | EP2093293A2 G-Protein coupled receptors |
| 08/26/2009 | EP2093214A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 08/26/2009 | EP2091955A1 Alkoxy compounds for disease treatment |
| 08/26/2009 | EP2091529A1 Use of l-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases |
| 08/26/2009 | EP2091522A1 Nutritional supplement composition for treatment of ocular diseases |
| 08/26/2009 | EP2091521A1 Anticonvulsive pharmaceutical compositions |
| 08/26/2009 | EP1911746B1 The substance having antioxidant, geroprotective and anti-ischemic activity and method for preparing thereof |
| 08/26/2009 | EP1506951B9 Method for the preparation of total salvianolic acid |
| 08/26/2009 | EP1423428B1 Antibodies that block fgfr3 activation, methods of screening for and uses thereof |
| 08/26/2009 | EP1218375B1 Pharmaceutically active sulfonyl amino acid derivatives |
| 08/26/2009 | CN101516385A Treatment of excessive neovascularization |
| 08/26/2009 | CN101516377A New medical use of triazine derivatives |
| 08/26/2009 | CN101514177A Method for extracting lutein from marigold particles |
| 08/26/2009 | CN101513389A Oral puerarin nano suspension for improving bioavailability of puerarin |
| 08/26/2009 | CN101513386A Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 08/26/2009 | CN100531764C Traditional Chinese medicine for treating deaf |
| 08/26/2009 | CN100531714C Preparing method of concentrated Shuanghuanglian oral liquid |
| 08/25/2009 | US7579367 Aryl substituted pyridines and the use thereof |
| 08/25/2009 | US7579347 Vanilloid receptor ligands and their use in treatments |
| 08/25/2009 | US7579188 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 08/25/2009 | US7579166 lysosomal enzyme having a mannose-6-phosphate-containing acidic sugar chain; a labeling marker for transporting into lysosomes; used as a drug effective in treatment of human lysosomal enzyme deficiencies |
| 08/25/2009 | CA2505086C Ophthalmic compositions for treating ocular hypertension |
| 08/25/2009 | CA2439078C Composition improving age-related physiological deficits and increasing longevity |
| 08/25/2009 | CA2375671C 4-phenyl-pyrimidine derivatives |
| 08/25/2009 | CA2366932C Cyclic protein tyrosine kinase inhibitors |
| 08/20/2009 | WO2009103053A1 Fluoroquinolone derivatives for ophthalmic applications |
| 08/20/2009 | WO2009102931A1 Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions |
| 08/20/2009 | WO2009102715A2 Peptide therapy for ocular herpes infections |
| 08/20/2009 | WO2009102418A1 Methods for the treatment and prevention of age-related retinal dysfunction |
| 08/20/2009 | WO2009102021A1 Treatment of retinal disease by activation of the function of bone marrow-derived stem cell or progenitor cell thereof |
| 08/20/2009 | WO2009100617A1 Polypeptide inhibiting angiogenesis and applicaton thereof |
| 08/20/2009 | WO2008139261A3 Omega-3 lipid compound |
| 08/20/2009 | US20090209632 Percutaneously Absorptive Ophthalmic Preparation Comprising Olopatadine |
| 08/20/2009 | US20090209627 RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS |
| 08/20/2009 | US20090209599 Eye drop containing roflumilast |
| 08/20/2009 | US20090209595 Method of treating of demyelinating diseases or conditions |
| 08/20/2009 | US20090209594 Method of treating of demyelinating diseases or conditions |
| 08/20/2009 | US20090209455 Vitreous administration of erythropoietin |
| 08/20/2009 | US20090208595 Extract of plant Dendrobii caulis and preparing process thereof |
| 08/20/2009 | US20090208462 Methods of Treatment |
| 08/20/2009 | CA2714580A1 Fluoroquinolone derivatives for ophthalmic applications |
| 08/20/2009 | CA2714530A1 Methods for the treatment and prevention of age-related retinal dysfunction |
| 08/19/2009 | EP2090589A1 Albumin-fused Kunitz domain peptides |
| 08/19/2009 | EP2090314A1 Ophthalmic aqeous liquid preparation |
| 08/19/2009 | EP2089016A2 Method for treatment of macular degeneration |
| 08/19/2009 | EP1362096B1 Pigmentary epithelium cell of the eye, the production thereof and the use of the same for treating diseases of the eye or of the central nervous system |
| 08/19/2009 | EP1255829B1 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
| 08/19/2009 | EP1187918B9 Tek antagonists |
| 08/19/2009 | CN101511357A Method for the treatment and prevention of ocular disorders |
| 08/19/2009 | CN100528874C Pyrrolo [2,3d] pyrimidine compositions and their use |
| 08/18/2009 | US7576241 e.g. 2-hydroxy-5-methoxy-N-{2-[4-[(2-thienyl(imino)methyl)amino]phenyl]ethyl)}-benzamide; nitric oxide NO-synthase enzymes inhibitor; selective or non selective traps for reactive oxygen species; antiproliferative, antiinflammatory agent |
| 08/18/2009 | US7576204 (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide; inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer |
| 08/18/2009 | US7576114 6-(4-Bromo-2-chloro-phenylamino)-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; anticarcinogenic, antiproliferative, and antiinflammatory agents; mitogen-activated protein kinase inhibitors |
| 08/18/2009 | US7576100 Muscarinic agonists |
| 08/18/2009 | US7576078 Tetrahydroquinoline analogues as muscarinic agonists |
| 08/18/2009 | CA2577233C Pharmaceutical composition containing angiotensin ii antagonist |
| 08/18/2009 | CA2412208C Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 08/18/2009 | CA2400268C Pyrrolopyrimidinone derivatives, process of preparation and use |
| 08/18/2009 | CA2392030C Urea compounds having muscarinic receptor antagonist activity |
| 08/18/2009 | CA2392028C Carbamate derivatives having muscarinic receptor antagonist activity |
| 08/18/2009 | CA2353835C Composition set and kit for use in intraocular surgery |
| 08/18/2009 | CA2174526C Pseudodipeptide product possessing an imidazole group and the therapeutic, cosmetological and agri-food applications of the said product |
| 08/13/2009 | WO2009100438A2 Compounds that enhance atoh-1 expression |
| 08/13/2009 | WO2009100348A2 Peptides and peptide mimetics to treat pathologies associated with eye disease |
| 08/13/2009 | WO2009100137A2 Magnetic cells for localizing delivery and tissue repair |
| 08/13/2009 | WO2009100057A1 Substituted cyclopentanes having prostaglandin activity |